PhaseBio Appoints Richard A. van den Broek to Board of Directors
March 04 2019 - 8:30AM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for orphan diseases, today
announced the appointment of Richard A. van den Broek to its board
of directors, effective February 27, 2019.
“I am delighted to welcome Richard to PhaseBio’s
board of directors,” said Jonathan P. Mow, Chief Executive
Officer of PhaseBio. “Richard’s prior board experience and
deep understanding of biopharmaceutical capital markets will be of
great value as we continue to execute corporate and clinical
milestones and build value for our stockholders.”
Mr. van den Broek has nearly 30 years of
experience in financial strategy and investment fund management in
the life sciences industry. He currently serves as managing partner
of HSMR Advisors, an investment fund focused on the biotechnology
industry. Prior to joining HSMR Advisors in 2004, Mr. van den Broek
served as partner at Cooper Hill Partners. Earlier in his career,
Mr. van den Broek was a biotechnology analyst at Hambrecht &
Quist, Merrill Lynch and Oppenheimer & Co. Inc. Mr. van den
Broek holds a bachelor’s degree from Harvard University and is a
Chartered Financial Analyst. Mr. van den Broek has previously
served as a Director at companies including Pharmacyclics, Inc.,
Response Genetics, Inc., and Celldex Therapeutics, Inc.
“I am pleased to be joining PhaseBio’s board of
directors at this exciting time for the company,” said Mr. van den
Broek. “I look forward to contributing to PhaseBio’s continued
success as the company advances its pipeline of innovative
therapies with the potential to transform the lives of people
living with orphan diseases.”
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies to treat orphan diseases,
with an initial focus on cardiopulmonary disorders. The company’s
lead development candidate is PB2452, a novel reversal agent for
the antiplatelet therapy ticagrelor. PhaseBio is also leveraging
its proprietary elastin-like polypeptide (“ELP”) technology
platform to develop therapies with the potential for less-frequent
dosing and improved pharmacokinetics. PhaseBio’s second product
candidate PB1046, which is based on ELP, is a once-weekly
vasoactive intestinal peptide receptor agonist for the treatment of
pulmonary arterial hypertension.
PhaseBio is located in Malvern, PA and San
Diego, CA. For more information, please
visit www.phasebio.com.
Investor Contact:John SharpPhaseBio
Pharmaceuticals, Inc. Chief Financial Officer(610)
981-6506john.sharp@phasebio.com
Media Contact:Sarah Hall6 Degrees(215)
313-5638shall@6degreespr.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Jun 2024 to Jul 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Jul 2023 to Jul 2024